WuXi XDC

Welcome to WuXi XDC’s Newsletter - A Year of Impact! As we approach the end of 2024, it is a time to summarize the extraordinary journey that WuXi XDC has embarked in 2024. 2024 has been a year filled with an abundance of accomplishments and memorable moments. Let’s discover the highlights of WuXi XDC in 2024 together.

In Case YOU MISS IT! View Now on Demand: "Integrated Analytical Platform Accelerates CMC Bioconjugate Development”. In this webinar, Dr. ZHIGUO LI, Executive Director, Head of Analytical Development and Characterization Team at WuXi XDC delved into the development of physicochemical and biochemical analysis methods for various types of bioconjugates, and presented an integrated analytical strategy to address development hurdles and accelerate the, CMC timeline. Access the on-demand webinar here: https://lnkd.in/gqN8SRtw You are welcome to contact us via the following link if you have any questions about the webinar or would like to schedule a meeting with us. https://lnkd.in/eCgHTVqf

💖✨ A New Year's Greeting: Cheers to 2025! 🥳🎉✨ Wishing you all a Happy New Year filled with prosperity, joy, and new adventures!

🎄✨Seasonal Greetings and Merry Christmas! 🌟 As the festive lights shine bright and the holiday cheer fills the air, we want to take a moment to wish you a Merry Christmas! May this Christmas season bring you joy and peace, and precious memories. 🎄 🎄 🎄

WuXi XDC (stock code: 2268.HK), a global leader in providing end-to-end CRDMO services for antibody-drug conjugates (ADC) and other bioconjugates, recently announced that its state-of-the-art dual-function ADC production facility, XBCM2 Line2, has officially commenced operations. The facility‘s inaugural integrated process project, encompassing cell culture，antibody purification，and the production of conjugated bulk drug substances, has been successfully completed. This landmark achievement underscores WuXi XDC’s commitment to expanding capacity and driving technological innovation, solidifying its position at the forefront of integrated biopharmaceutical processes. For more detailed information about this news, please click the following link. https://lnkd.in/g38MNn93

In the intricate world of biologics development, especially for ADCs/Bioconjugates area, collaboration is pivotal for propelling innovation and bringing in novel treatments. At least 82 partnership deals and 68 licensing deals in ADCs during 2023 to mid-2024 were announced, based upon a report by Hanson Wade. At the recent Global XDC Innovation Conference, hosted by WuXi XDC, a panel of global biopharma and biotech experts engaged in a closed-door discussion about the challenges of partnering with biotech companies and the art of selecting the right collaborators. This article highlights the insights from these discussions, offering strategies for those looking to navigate the complex landscape of ADCs/bioconjugates collaborations. Click on the image below to view the full insightful article.

We are thrilled to announce that WuXi XDC will collaborate with Enmore Bio, as a co-organizer to jointly host the 2025 BPD @Singapore Summit (Biopharmaceutical Bioprocess Development Summit) during September 24-26, 2025, and to host the XDC Innovation Development Sub-forum. The summit will bring together biopharmaceutical companies and research institutions from China, Singapore, and other countries in the world. With a focus on Southeast Asia, Europe, and the Americas, it aims to foster the transformation of advanced technologies into innovative drug production. Connect with us to secure a spot: https://lnkd.in/guvvwrnY

The world of antibody-drug conjugates (ADCs) is rapidly evolving, with companies in various circumstance seeking to accelerate their progress towards Biologics License Applications (BLAs). Process development (PD) and manufacturing stand out as critical activities that companies with proprietary technologies tend to keep PD in-house, while for companies without their own manufacturing facilities, many activities are conducted externally. In a closed-door symposium at our Global XDC Innovation Conference, a panel of ADC experts with a global footprint spanning China, Singapore, and the US, has delved into the complexities of the journey from late-stage ADC development to BLA and the importance of strategic selection of CDMO at a unique global perspective. Click on the image below to view the full insightful article.

🎉🌟 Our LinkedIn account has surpassed 10,000 LinkedIn followers since we posted the first post in early February this year! Your support motivates us to keep sharing the latest innovations in ADC and other bioconjugates through our integrated CRDMO services. We'd like to take this opportunity to thank all the 10,000+ followers, and invite more biopharmaceutical professionals to follow our LinkedIn account.

📣 Don't miss our upcoming insightful webinar in collaboration with BioPharm International for “Integrated Analytical Platform Accelerates CMC Bioconjugate Development. Dr. ZHIGUO LI, Executive Director, Head of Analytical Development and Characterization Team at WuXi XDC, will delve into the development of physicochemical and biochemical analysis methods for various types of bioconjugates, and present an integrated analytical strategy to address development hurdles and accelerate the CMC timeline. Find more info and to register: https://lnkd.in/gqN8SRtw